PDD Holdings Revenue Growth Potential Amid Regulatory Resolution According to Morgan Stanley UK Police Chiefs Push for Social Media Block for Under16s Regulatory Risks for Tech Firms Micron Reaches 1 Trillion Market Cap Milestone as AIDriven Memory Demand Fuels Stock Surge French Open Prize Money Dispute Top Players Curtail Media Duties in Protest Trainline Upgrades Fiscal Year Guidance Again Signaling Growth Momentum Treasury Yield Surge Prompts Bond Investors to Seek Alternative FixedIncome Opportunities NTZ Q4 2011 Earnings Significant EPS Miss as Company Reports WiderthanExpected Loss HZO Q1 2026 Earnings EPS Misses Estimates but Stock Edges Higher Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses SLI Q1 2026 Earnings Narrower Than Expected Loss as Company Advances Lithium Projects CTEV Q1 2026 Earnings Significant EPS Miss Amidst Operational Challenges Wynn Resorts WYNN Surges 34 as Bulls Test Key Resistance at 10628 Omega Healthcare Investors Slides 106 as Support Levels Come into Focus mF International Limited MFI Slips Over 10 as Selling Pressure Intensifies Carters Inc CRI Gains 25 as Shares Bounce from Support CapsoVision Inc CV Advances 118 as Price Moves Toward Resistance Ferraris EV Ambition Raises Questions About Brand Heritage and Myth CWCO Q1 2026 Earnings EPS Misses Estimates by 1327 as Stock Edges Higher Primo Brands Corporation PRMB Sees Upside Momentum Stock Gains Over 2 as It Approaches Key Resistance PCRX Q1 2026 Earnings EPS Surpasses Estimates on Strong Operational Performance Mesa Royalty Trust MTR Q4 2025 Earnings Modest EPS as Royalty Income Continues to Reflect Stable Production JRVR Q1 2026 Earnings EPS Misses Estimates by Wide Margin Stock Declines Exodus Movement Inc EXOD Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Revenue Data Unavailable BURU Q3 2023 Earnings Significant Loss Per Share Amid PreRevenue Stage HCA Q1 2026 Earnings EPS Misses Estimates Amid Narrow Surprise and Flat Stock Reaction Lisata Therapeutics Q3 2025 Earnings NarrowerthanExpected Loss as Biotech Advances Clinical Pipeline